Vantage logo

Gout flop leaves Sobi red-faced

SEL-212 fails to beat Krystexxa in phase II, but why did Sobi pay $100m for the asset in June and then put it into phase III?

Vantage logo

Myovant socks it to Orilissa

Two years after Abbvie’s disappointing launch of Orilissa Myovant hails the development of something much better.